| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA686: Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) |
|
Medicine details |
|
| Medicine name | blinatumomab (Blincyto®) |
| Formulation | 38.5 micrograms powder for concentrate for solution for infusion |
| Reference number | 2994 |
| Indication | Monotherapy for the treatment of adults with CD19 positive relapsed or refractory B precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options |
| Company | Amgen Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/05/2021 |
| NICE guidance | |